Advanced searches left 3/3

Lysosomal Storage Disorders - DOAJ

Summarized by Plex Scholar
Last Updated: 02 April 2022

* If you want to update the article please login/register

Establishment of Cutoff Values for Newborn Screening of Six Lysosomal Storage Disorders by Tandem Mass Spectrometry

ObjectiveLysosomal storage disorders are becoming increasingly important in newborn screening for LSDs, and tandem mass spectrometry is increasingly used in newborn screening for LSDs by measuring enzymatic activity in dried blood spots. Methods & Co. In this research, we used MS/MS to test for LSDs from various maternity hospitals in six cities in Shandong province, including Jinan, Dezhou, Heze, Linyi, Weifang, and Zibo; the experimental results were evaluated using a Waters Xevo TQD tandem mass spectrometer, which were analysed using MassLynx V4. 1. The low temperature could be a reason why the enzyme activity cutoff value has seasonal variations.

Source link: https://doi.org/10.3389/fped.2022.814461


Insight into the Role of Extracellular Vesicles in Lysosomal Storage Disorders

These proteins have also been shown to be released extracellularly by EVs in neurodegenerative disorders characterized by increased toxic proteins, but it is unclear to what extent the intracellular storage of undigested materials itself has beneficial/adverse effects. Undigested substrates within the endosomal−lysosomal system are found, either as a result of genetic mutations in lysosomal proteins or to therapy with pharmacological agents. We review findings on the release of EVs from lysosomal and autophagic dysfunction, with a focus on studies examining the release of EVs in LSD models of both genetic and pharmacological origins. A better understanding of EV-releasing pathways in lysosomal stress conditions will reveal more insight into the role of EVs in both reducing intracellular storage of undigested products and spreading the pathology to the neighboring tissue.

Source link: https://doi.org/10.3390/genes10070510


Neurologic abnormalities in mouse models of the lysosomal storage disorders mucolipidosis II and mucolipidosis III γ.

Mutations in the / subunit precursor gene cause the acute lysosomal storage disorder mucolipidosis II or the more subtle mucolipidosis III alpha/beta, according to mucolipidosis III alpha/beta, although mutations in the subunit gene cause mucolipidosis III alpha/beta, while mutations in the subunit gene result in mucolipidosis III gamma Here we discuss the neurologic implications of mouse models of ML II and ML III. Acid hydrolase phosphorylation in ML II mice has been a complete lack of acid hydrolase phosphorylation, resulting in the depletion of acid hydrolases in mesenchymal-derived cells. The ML III mice have partial phosphorylation. The ML II mice diedegeneration, neuronal degeneration, astrocytosis, microgliosis, and Purkinje cell depletion, which was present at 4 months, but ML III mice have mild to moderate astrocytosis and microgliosis at 12 months. Both models produce the ganglioside GM2, but only ML II mice produce fucosylated glycans.

Source link: https://doi.org/10.1371/journal.pone.0109768


A Comparative Effectiveness Study of Newborn Screening Methods for Four Lysosomal Storage Disorders

Multiplexed enzyme assays have been used in many US states, Japan, and Taiwan, using either tandem mass spectrometry or digital microfluidics. It has also been suggested that an immunocapture device be used in another multiplex assay. These assays were evaluated in a prospective comparative effectiveness study using nearly 100,000 fresh newborn dried blood spot specimens. To determine the ability of each assay vs. the traditional result interpretation based on analyte-specific reference ranges and cutoffs, amputation of the traditional result interpretation was created using the software Collaborative Laboratory Integrated Reports. This report found that all three platforms have high sensitivity, and the use of CLIR technologies significantly raises the results of each platform, while reducing the demand for 2nd tier testing by 66% to 95%.

Source link: https://doi.org/10.3390/ijns6020044


Lysosomal Storage Disorders and Malignancy

Polyclonal and monoclonal gammopathy among patients with GD has increased frequency, according to studies. Embedded T-follicular helper cells were present and constitutively promoted the occurrence of a T-follicular helper phenotype, and precipitantly promoted the expression of a T-follicular helper phenotype by injection of these lipids; downstream induction of germinal center B cells, hypergammaglobulinemia, and antilipid manufacturing was found in an affected mouse model; research into an affected mouse model revealed GL1-22- and LGL1-specific NKT cells were present and LGL1-specific NKT cells were present and phenotype of pheno phenotype; phenotively promoted the production of phenotype; lipids; In 33% of sporadic human monoclonal gammopathies, clonal immunoglobulin is also present in clonal gammopathies, which are also specific to the lysolipids LGL1 and lysophosphatidylcholine. Chronic antigenic stimulation by the abnormal lipid storage and associated immune dysregulation may be the triggering factor for increased incidence of monoclonal and polyclonal gammopathies, as well as an elevated risk of multiple myeloma in patients with GD.

Source link: https://doi.org/10.3390/diseases5010008


The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience

Patients with Lysosomal Storage Diseases (ERT) are often required recurrent courses of ERT. With a focus on the challenges and difficulties associated with these catheters, we reviewed our results with port-a-caths in patients with LSDs. Among 245 adult patients treated with ERT, twenty patients had a port-a-cath installed due to poor venous access. Six patients were using their first port, while five other patients had their port-a-caths replaced at least once, whereas five other patients' had their port-a-caths replaced at least once. The majority of patients with active port-a-caths never missed more than one consecutive infusion, though one patient missed two consecutive infusions while away on holiday.

Source link: https://doi.org/10.1016/j.ymgmr.2017.10.003


A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia

Lysosomal storage diseases are a group of about 50 inborn metabolic disorders characterized by the accumulation of partially or non-degraded molecules in the lysosomal biogenesis or modulators of lysosomal biosynthesis or modulators of lysosomal storage disease. Significant strides have been made in the diagnosis, monitoring, and treatment of LSDs patients. We summarized the evidence that has been published in this study, including the Colombian experience in LSDs. Noteworthy, the enzyme assay in dried blood samples, which resulted in a 5-fold rise in the detection of LSD patients, indicating that these disorders are still undiagnosed in the United States. The findings in this review will help inform a wide variety of LSDs in Colombia's knowledge and will also contribute to the formulation of public policies and the identification of research opportunities.

Source link: https://doi.org/10.1016/j.heliyon.2020.e03635


Impact, Characterization, and Rescue of Pre-mRNA Splicing Mutations in Lysosomal Storage Disorders

This paper gives an overview of the effects of splicing mutations in LSDs and the associated therapeutic methods that are currently being investigated in these disorders.

Source link: https://doi.org/10.3390/genes9020073


Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises

Both aiming to compensate for the enzymatic loss of the underlying mutated lysosomal enzymes that are responsible for the enzymatic breakdown of the underlying mutated lysosomal enzymes. In recent years, small molecular weight compounds such as pharmaceutical chaperones and proteostasis regulators have been used in recent years to be promising methods for overcoming some of these protein processing defects. Multiple LSDs like migalastat in the treatment of Fabry disease have already been approved for clinical use, but others are still under study or in clinical trials such as Ambroxol hydrochloride and Pyrimethamine. In this series, we're giving a general overview of LSDs, including the use of PCs and proteostasis inhibitors as therapeutic targets for some LSDs as therapeutic targets.

Source link: https://doi.org/10.3389/fphar.2017.00448


Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders

A group of rare, life-threatening genetic disorders affecting intralysosomal digestion are Lysosomal storage diseases, characterized by a defect in one of the various enzymes responsible for intralysosomal digestion. Despite the fact that no cure is available for any LSD, a few treatment options do exist. Traditionally, attempts have mainly targeted the enzyme's functional degradation by injection of a recombinant formulation in a process called enzyme replacement therapy, with no effect on neuropathology.

Source link: https://doi.org/10.3390/ijms17071065

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions